Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Freeman

Showing results (311-320 of 330) with videos related to

Pageof 33
Sort By:
Trials|October 5, 2023
Testing the combination of Feeling Safe and peer counselling against formulation-based cognitive behaviour therapy to promote psychological wellbeing in people with persecutory delusions: study protocol for a randomized controlled trial (the Feeling Safe-NL Trial)Eva Tolmeijer, Felicity Waite, Louise Isham, et al.
Health Technology Assessment (Winchester, England)|January 26, 2021
Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCTAnthony P Morrison, Melissa Pyle, Rory Byrne, et al.
Schizophrenia Bulletin|July 18, 2014
How cannabis causes paranoia: using the intravenous administration of ∆9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoiaDaniel Freeman, Graham Dunn, Robin M Murray, et al.
Schizophrenia Research|November 7, 2022
Agoraphobic avoidance in patients with psychosis: Severity and response to automated VR therapy in a secondary analysis of a randomised controlled clinical trialDaniel Freeman, Sinéad Lambe, Ushma Galal, et al.
The Lancet. Psychiatry|April 8, 2022
Automated virtual reality therapy to treat agoraphobic avoidance and distress in patients with psychosis (gameChange): a multicentre, parallel-group, single-blind, randomised, controlled trial in England with mediation and moderation analysesDaniel Freeman, Sinéad Lambe, Thomas Kabir, et al.
Psychological Medicine|April 3, 2023
The Oxford Agoraphobic Avoidance ScaleSinead Lambe, Jessica C Bird, Bao Sheng Loe, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2010
2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeuticsQingping Zeng, Matthew P Bourbeau, G Erich Wohlhieter, et al.
Behavioural and Cognitive Psychotherapy|February 15, 2022
Understanding agoraphobic avoidance: the development of the Oxford Cognitions and Defences Questionnaire (O-CDQ)Laina Rosebrock, Sinéad Lambe, Sophie Mulhall, et al.
Trials|July 6, 2019
Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS)Melissa Pyle, Matthew R Broome, Emmeline Joyce, et al.
Psychological Medicine|April 28, 2022
Virtual reality (VR) therapy for patients with psychosis: satisfaction and side effectsDaniel Freeman, Laina Rosebrock, Felicity Waite, et al.
Pageof 33

Showing results (311-320 of 330) with videos related to

Sort By:
Pageof 33
Trials|October 5, 2023
Testing the combination of Feeling Safe and peer counselling against formulation-based cognitive behaviour therapy to promote psychological wellbeing in people with persecutory delusions: study protocol for a randomized controlled trial (the Feeling Safe-NL Trial)Eva Tolmeijer, Felicity Waite, Louise Isham, et al.
Health Technology Assessment (Winchester, England)|January 26, 2021
Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCTAnthony P Morrison, Melissa Pyle, Rory Byrne, et al.
Schizophrenia Bulletin|July 18, 2014
How cannabis causes paranoia: using the intravenous administration of ∆9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoiaDaniel Freeman, Graham Dunn, Robin M Murray, et al.
Schizophrenia Research|November 7, 2022
Agoraphobic avoidance in patients with psychosis: Severity and response to automated VR therapy in a secondary analysis of a randomised controlled clinical trialDaniel Freeman, Sinéad Lambe, Ushma Galal, et al.
The Lancet. Psychiatry|April 8, 2022
Automated virtual reality therapy to treat agoraphobic avoidance and distress in patients with psychosis (gameChange): a multicentre, parallel-group, single-blind, randomised, controlled trial in England with mediation and moderation analysesDaniel Freeman, Sinéad Lambe, Thomas Kabir, et al.
Psychological Medicine|April 3, 2023
The Oxford Agoraphobic Avoidance ScaleSinead Lambe, Jessica C Bird, Bao Sheng Loe, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2010
2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeuticsQingping Zeng, Matthew P Bourbeau, G Erich Wohlhieter, et al.
Behavioural and Cognitive Psychotherapy|February 15, 2022
Understanding agoraphobic avoidance: the development of the Oxford Cognitions and Defences Questionnaire (O-CDQ)Laina Rosebrock, Sinéad Lambe, Sophie Mulhall, et al.
Trials|July 6, 2019
Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS)Melissa Pyle, Matthew R Broome, Emmeline Joyce, et al.
Psychological Medicine|April 28, 2022
Virtual reality (VR) therapy for patients with psychosis: satisfaction and side effectsDaniel Freeman, Laina Rosebrock, Felicity Waite, et al.
Pageof 33